{"transactions":[{"id":3347080,"issuer":{"id":4261,"kind":"organization","name":"TransMedics Group, Inc.","symbol":"TMDX"},"owners":[{"id":664,"kind":"organization","name":"UNITED THERAPEUTICS Corp","symbol":"UTHR","position":1,"cik":"0001082554","reported_name":"UNITED THERAPEUTICS Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153230,"kind":"person","name":"Lung Biotechnology PBC","position":2,"cik":"0001774528","reported_name":"Lung Biotechnology PBC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-10T21:31:00.000Z","date":"2019-12-09","kind":"sale","acquired":false,"shares":500000,"price":18.75,"value":9375000.0,"ownership":{"direct":false,"nature":"By Lung Biotechnology PBC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported as being indirectly beneficially owned by United Therapeutics Corporation are directly beneficially owned by Lung Biotechnology PBC. Lung Biotechnology PBC is a wholly-owned subsidiary of United Therapeutics Corporation."}],"balance_after":2053240,"source":{"system":"sec-edgar","filing":"0001104659-19-071451","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1082554/000110465919071451/a4.xml","form_type":"4"}},{"id":3538273,"issuer":{"id":4261,"kind":"organization","name":"TransMedics Group, Inc.","symbol":"TMDX"},"owners":[{"id":664,"kind":"organization","name":"UNITED THERAPEUTICS Corp","symbol":"UTHR","position":1,"cik":"0001082554","reported_name":"UNITED THERAPEUTICS Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153230,"kind":"person","name":"Lung Biotechnology PBC","position":2,"cik":"0001774528","reported_name":"Lung Biotechnology PBC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series F Convertible Preferred Stock","published_at":"2019-05-06T21:32:50.000Z","date":"2019-05-06","kind":"exercise","acquired":false,"shares":2374109,"ownership":{"direct":false,"nature":"By Lung Biotechnology PBC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Preferred Stock reported herein is preferred stock of TransMedics, Inc.  Immediately prior to the closing of the Issuer's initial public offering, pursuant to the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019, such preferred stock of TransMedics, Inc. was converted into shares of common stock of the Issuer based on (i) the one-for-one ratio on which such shares of preferred stock of TransMedics Inc. were convertible into shares of common stock of TransMedics Inc. according to their terms and (ii) the 3.5-for-one ratio on which shares of common stock of TransMedics, Inc. were converted into shares of common stock of the Issuer.  The preferred stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The Preferred Stock reported herein is preferred stock of TransMedics, Inc.  Immediately prior to the closing of the Issuer's initial public offering, pursuant to the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019, such preferred stock of TransMedics, Inc. was converted into shares of common stock of the Issuer based on (i) the one-for-one ratio on which such shares of preferred stock of TransMedics Inc. were convertible into shares of common stock of TransMedics Inc. according to their terms and (ii) the 3.5-for-one ratio on which shares of common stock of TransMedics, Inc. were converted into shares of common stock of the Issuer.  The preferred stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Preferred Stock reported herein is preferred stock of TransMedics, Inc.  Immediately prior to the closing of the Issuer's initial public offering, pursuant to the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019, such preferred stock of TransMedics, Inc. was converted into shares of common stock of the Issuer based on (i) the one-for-one ratio on which such shares of preferred stock of TransMedics Inc. were convertible into shares of common stock of TransMedics Inc. according to their terms and (ii) the 3.5-for-one ratio on which shares of common stock of TransMedics, Inc. were converted into shares of common stock of the Issuer.  The preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Preferred Stock reported herein is preferred stock of TransMedics, Inc.  Immediately prior to the closing of the Issuer's initial public offering, pursuant to the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019, such preferred stock of TransMedics, Inc. was converted into shares of common stock of the Issuer based on (i) the one-for-one ratio on which such shares of preferred stock of TransMedics Inc. were convertible into shares of common stock of TransMedics Inc. according to their terms and (ii) the 3.5-for-one ratio on which shares of common stock of TransMedics, Inc. were converted into shares of common stock of the Issuer.  The preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Preferred Stock reported herein is preferred stock of TransMedics, Inc.  Immediately prior to the closing of the Issuer's initial public offering, pursuant to the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019, such preferred stock of TransMedics, Inc. was converted into shares of common stock of the Issuer based on (i) the one-for-one ratio on which such shares of preferred stock of TransMedics Inc. were convertible into shares of common stock of TransMedics Inc. according to their terms and (ii) the 3.5-for-one ratio on which shares of common stock of TransMedics, Inc. were converted into shares of common stock of the Issuer.  The preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported as being indirectly beneficially owned by United Therapeutics Corporation are directly beneficially owned by Lung Biotechnology PBC. Lung Biotechnology PBC is a wholly-owned subsidiary of United Therapeutics Corporation."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":678317},"source":{"system":"sec-edgar","filing":"0001104659-19-027214","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1082554/000110465919027214/a4.xml","form_type":"4"}},{"id":3538272,"issuer":{"id":4261,"kind":"organization","name":"TransMedics Group, Inc.","symbol":"TMDX"},"owners":[{"id":664,"kind":"organization","name":"UNITED THERAPEUTICS Corp","symbol":"UTHR","position":1,"cik":"0001082554","reported_name":"UNITED THERAPEUTICS Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153230,"kind":"person","name":"Lung Biotechnology PBC","position":2,"cik":"0001774528","reported_name":"Lung Biotechnology PBC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Convertible Preferred Stock","published_at":"2019-05-06T21:32:50.000Z","date":"2019-05-06","kind":"exercise","acquired":false,"shares":6562232,"ownership":{"direct":false,"nature":"By Lung Biotechnology PBC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Preferred Stock reported herein is preferred stock of TransMedics, Inc.  Immediately prior to the closing of the Issuer's initial public offering, pursuant to the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019, such preferred stock of TransMedics, Inc. was converted into shares of common stock of the Issuer based on (i) the one-for-one ratio on which such shares of preferred stock of TransMedics Inc. were convertible into shares of common stock of TransMedics Inc. according to their terms and (ii) the 3.5-for-one ratio on which shares of common stock of TransMedics, Inc. were converted into shares of common stock of the Issuer.  The preferred stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The Preferred Stock reported herein is preferred stock of TransMedics, Inc.  Immediately prior to the closing of the Issuer's initial public offering, pursuant to the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019, such preferred stock of TransMedics, Inc. was converted into shares of common stock of the Issuer based on (i) the one-for-one ratio on which such shares of preferred stock of TransMedics Inc. were convertible into shares of common stock of TransMedics Inc. according to their terms and (ii) the 3.5-for-one ratio on which shares of common stock of TransMedics, Inc. were converted into shares of common stock of the Issuer.  The preferred stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Preferred Stock reported herein is preferred stock of TransMedics, Inc.  Immediately prior to the closing of the Issuer's initial public offering, pursuant to the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019, such preferred stock of TransMedics, Inc. was converted into shares of common stock of the Issuer based on (i) the one-for-one ratio on which such shares of preferred stock of TransMedics Inc. were convertible into shares of common stock of TransMedics Inc. according to their terms and (ii) the 3.5-for-one ratio on which shares of common stock of TransMedics, Inc. were converted into shares of common stock of the Issuer.  The preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Preferred Stock reported herein is preferred stock of TransMedics, Inc.  Immediately prior to the closing of the Issuer's initial public offering, pursuant to the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019, such preferred stock of TransMedics, Inc. was converted into shares of common stock of the Issuer based on (i) the one-for-one ratio on which such shares of preferred stock of TransMedics Inc. were convertible into shares of common stock of TransMedics Inc. according to their terms and (ii) the 3.5-for-one ratio on which shares of common stock of TransMedics, Inc. were converted into shares of common stock of the Issuer.  The preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Preferred Stock reported herein is preferred stock of TransMedics, Inc.  Immediately prior to the closing of the Issuer's initial public offering, pursuant to the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019, such preferred stock of TransMedics, Inc. was converted into shares of common stock of the Issuer based on (i) the one-for-one ratio on which such shares of preferred stock of TransMedics Inc. were convertible into shares of common stock of TransMedics Inc. according to their terms and (ii) the 3.5-for-one ratio on which shares of common stock of TransMedics, Inc. were converted into shares of common stock of the Issuer.  The preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported as being indirectly beneficially owned by United Therapeutics Corporation are directly beneficially owned by Lung Biotechnology PBC. Lung Biotechnology PBC is a wholly-owned subsidiary of United Therapeutics Corporation."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1874923},"source":{"system":"sec-edgar","filing":"0001104659-19-027214","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1082554/000110465919027214/a4.xml","form_type":"4"}},{"id":3538271,"issuer":{"id":4261,"kind":"organization","name":"TransMedics Group, Inc.","symbol":"TMDX"},"owners":[{"id":664,"kind":"organization","name":"UNITED THERAPEUTICS Corp","symbol":"UTHR","position":1,"cik":"0001082554","reported_name":"UNITED THERAPEUTICS Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153230,"kind":"person","name":"Lung Biotechnology PBC","position":2,"cik":"0001774528","reported_name":"Lung Biotechnology PBC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-06T21:32:50.000Z","date":"2019-05-06","kind":"exercise","acquired":true,"shares":2553240,"ownership":{"direct":false,"nature":"By Lung Biotechnology PBC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Preferred Stock reported herein is preferred stock of TransMedics, Inc.  Immediately prior to the closing of the Issuer's initial public offering, pursuant to the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019, such preferred stock of TransMedics, Inc. was converted into shares of common stock of the Issuer based on (i) the one-for-one ratio on which such shares of preferred stock of TransMedics Inc. were convertible into shares of common stock of TransMedics Inc. according to their terms and (ii) the 3.5-for-one ratio on which shares of common stock of TransMedics, Inc. were converted into shares of common stock of the Issuer.  The preferred stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Preferred Stock reported herein is preferred stock of TransMedics, Inc.  Immediately prior to the closing of the Issuer's initial public offering, pursuant to the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019, such preferred stock of TransMedics, Inc. was converted into shares of common stock of the Issuer based on (i) the one-for-one ratio on which such shares of preferred stock of TransMedics Inc. were convertible into shares of common stock of TransMedics Inc. according to their terms and (ii) the 3.5-for-one ratio on which shares of common stock of TransMedics, Inc. were converted into shares of common stock of the Issuer.  The preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported as being indirectly beneficially owned by United Therapeutics Corporation are directly beneficially owned by Lung Biotechnology PBC. Lung Biotechnology PBC is a wholly-owned subsidiary of United Therapeutics Corporation."}],"balance_after":2553240,"source":{"system":"sec-edgar","filing":"0001104659-19-027214","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1082554/000110465919027214/a4.xml","form_type":"4"}}]}